Εμφάνιση απλής εγγραφής

dc.creatorMontes, A.en
dc.creatorPerez-Pampin, E.en
dc.creatorJoven, B.en
dc.creatorCarreira, P.en
dc.creatorFernandez-Nebro, A.en
dc.creatorOrdonez, M. D.en
dc.creatorNavarro-Sarabia, F.en
dc.creatorMoreira, V.en
dc.creatorVasilopoulos, Y.en
dc.creatorSarafidou, T.en
dc.creatorCaliz, R.en
dc.creatorFerrer, M. A.en
dc.creatorCanete, J. D.en
dc.creatorde la Serna, A. R.en
dc.creatorMagallares, B.en
dc.creatorNarvaez, J.en
dc.creatorGomez-Reino, J. J.en
dc.creatorGonzalez, A.en
dc.date.accessioned2015-11-23T10:39:49Z
dc.date.available2015-11-23T10:39:49Z
dc.date.issued2015
dc.identifier10.2217/pgs.14.175
dc.identifier.issn1462-2416
dc.identifier.urihttp://hdl.handle.net/11615/31103
dc.description.abstractObjectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other Fc gamma R functional polymorphisms. Methods: Functional polymorphisms FCGR3A F158V, FCGR2B I223T and promoter VNTR in FCGRT were analyzed in up to 429 patients with RA. Response to TNFi was recorded during standard care at 3, 6 and 12 months of follow-up. Fixed effects meta-analysis of studies addressing FCGR3A F158V polymorphism, which is the most studied of these polymorphisms, was conducted with inverse variance weighting. Results: None of the functional polymorphisms were associated with change in DAS28. Meta-analysis of the seven studies (899 patients) with available data addressing association of FCGR3A F158V with response to TNFi in RA showed no association (OR: 1.11, 95% CI: 0.8-1.5; p = 0.5). Conclusion: None of the three functional polymorphisms in Fc gamma R genes showed association with response to TNFi in patients with RA. These negative results were obtained in spite of the larger size of this study relative to previous studies addressing the same polymorphisms. In addition, meta-analysis of FCGR3A F158V was also negative against the results provided by previous studies.en
dc.source.uri<Go to ISI>://WOS:000352027000005
dc.subjectadalimumaben
dc.subjectbiologicsen
dc.subjectbiomarkersen
dc.subjectetanercepten
dc.subjectFc receptoren
dc.subjectFCGRTen
dc.subjectgeneticsen
dc.subjectinfliximaben
dc.subjectrheumatoid arthritisen
dc.subjectTNF inhibitorsen
dc.subjectMODIFYING ANTIRHEUMATIC DRUGSen
dc.subjectCOLLEGE-OF-RHEUMATOLOGYen
dc.subjectALPHA-BLOCKINGen
dc.subjectAGENTSen
dc.subjectGAMMA RECEPTOR IIBen
dc.subjectCROHNS-DISEASEen
dc.subjectEULAR RECOMMENDATIONSen
dc.subjectMONOCLONAL-ANTIBODIESen
dc.subjectBIOLOGICAL RESPONSEen
dc.subjectTREATMENT OUTCOMESen
dc.subjectADCCen
dc.subjectACTIVITYen
dc.subjectPharmacology & Pharmacyen
dc.titleFCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitorsen
dc.typejournalArticleen


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής